3-Boc-3,8-二氮杂双环[3.2.1]辛烷 | 201162-53-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-Boc-3,8-二氮杂双环[3.2.1]辛烷
• 中文别名: 3,8-二氮杂双环[3.2.1]辛烷-3-甲酸叔丁酯
• 英文名称: tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate
• 英文别名: 3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester；3-Boc-3,8-diazabicyclo[3.2.1]octane；tert-butyl 3,8-diazabicyclo[3.2.1]octan-3-carboxylate；tert-butyl (1R, 5S)3,8-diazabicyclo[3.2.1]octane-3-carboxylate
• CAS: 201162-53-0
• 化学式: C₁₁H₂₀N₂O₂
• mdl: MFCD17016700
• 分子量: 212.292
• InChiKey: PSDAEKDIOQXLLC-UHFFFAOYSA-N

物化性质

• 沸点：
  295.4±15.0 °C(Predicted)
• 密度：
  1.076

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Boc-3,8-diazabicyclo[3.2.1]octane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Boc-3,8-diazabicyclo[3.2.1]octane
CAS number: 201162-53-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H20N2O2
Molecular weight: 212.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3,8-二氮杂双环[3.2.1]辛烷-3-甲酸叔丁酯是一种医药中间体，可用于合成新药物分子。据文献报道，它还可用于制备NLRP3抑制剂和RET激酶抑制剂。

反应信息

• 作为反应物：
  描述：

  3-Boc-3,8-二氮杂双环[3.2.1]辛烷 在 盐酸 、 偶氮二甲酸二叔丁酯 、 palladium 10% on activated carbon 、 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 methanesulfonato(2-dicyclohexylphosphino-2’,6’-di-i-propoxy-1,1’-biphenyl)(2’-methylamino-1,1‘-biphenyl-2-yl)palladium(II) 、 氢气 、 甲酸铵 、 sodium carbonate 、 potassium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 、 叔丁醇 为溶剂， 反应 74.5h， 生成 rac-5-[[1-[4-[2-[3-[3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]phenoxy]ethyl]piperazine-1-carbonyl]-4-piperidyl]oxy]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER
  [FR] COMPOSÉS BIFONCTIONNELS POUR LE TRAITEMENT DU CANCER

  摘要：

  该发明提供了式（I）的双功能化合物或其药用可接受的盐。式（I）。这些化合物通过靶向泛素化SMARCA2蛋白并随后的蛋白酶体降解来导致SMARCA2的降解，因此对于癌症的治疗是有用的。靶向配体的化学式为（TL）。

  公开号：

  WO2021083949A1
• 作为产物：
  描述：

  3-propionyl-3,8-diazabicyclo<3.2.1>octane 在 palladium on activated charcoal 盐酸 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 3.0h， 生成 3-Boc-3,8-二氮杂双环[3.2.1]辛烷
  参考文献：
  名称：

  单取代和二取代的3,8-二氮杂双环[3.2.1]辛烷衍生物作为与依巴替丁结构相关的止痛药：合成，活性和建模。

  摘要：

  合成了一系列3,8-二氮杂双环[3.2.1]辛烷，它们在3位（化合物1）或8位（化合物2）被氯代杂芳基环取代，作为强效天然止痛剂Epibatidine的潜在类似物。当在热板试验中测试时，大多数化合物显示出显着效果，最有趣的是3-（6-氯-3-吡啶并嗪基）-3,8-二氮杂双环[3.2.1]辛烷（1a）。在1 mg / kg的皮下剂量下，1a导致疼痛阈值显着增加，其作用持续约45分钟。1a在小鼠腹部收缩试验中以5 mg / kg的剂量也表现出良好的保护作用，而在20 mg / kg的剂量下，它完全阻止了动物的收缩。纳洛酮（1 mg / kg腹膜内）的给药不会拮抗其抗伤害感受，而美加明（2 mg / kg腹膜内）则能拮抗其伤害感受，因此暗示烟碱系统参与其作用。结合研究证实了对α4 beta 2 nAChR亚型的高度亲和力（Ki = 4.1 +/- 0.21 nM）。对三种不同细胞系的nAChR功

  DOI：

  10.1021/jm970427p

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• Novel amides useful for treating pain
  申请人：Zheng Zhu Guo

  公开号：US20050009841A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of formula (I) that useful in treating pain.

  本发明涉及一种用于治疗疼痛的化合物，其化学式为（I）。
• [EN] HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES POUR INHIBER L'ACTIVITÉ DE SHP2
  申请人：TAIHO PHARMACEUTICAL CO LTD

  公开号：WO2020022323A1

  公开（公告）日：2020-01-30

  A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.

  其中环A，Q，R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，X，a，b，c和d的化合物的化学式（I）：在规范中定义。
• Substituted diazabicycloalkane derivatives
  申请人：Basha Anwer

  公开号：US20050101602A1

  公开（公告）日：2005-05-12

  Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

  式(I)的化合物 Z-Ar 1 —Ar 2 (I) 其中Z是一种二氮杂双环胺，Ar 1 是一个5-或6-成员芳香环，Ar 2 选自未取代或取代的5-或6-成员杂芳基环；未取代或取代的双环杂芳基环；3,4-(亚甲二氧基)苯基；咔唑基；四氢咔唑基；萘基；和苯基；其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的病症或紊乱中有用。还公开了包含式(I)的化合物的药物组合物以及使用这些化合物和组合物的方法。
• CDK激酶抑制剂
  申请人：山东轩竹医药科技有限公司

  公开号：CN104910137B

  公开（公告）日：2017-04-19

  本发明属于医药技术领域，具体涉及通式(Ⅰ)所示的CDK激酶抑制剂、其药学上可接受的盐、其酯、其溶剂化物以及他们的立体异构体，其中R1、R2、R3、R4、R5、n如说明书中所定义。本发明还涉及这些化合物的制备方法，含有这些化合物的药物制剂和药物组合物，以及该化合物、其药学上可接受的盐、其酯、其溶剂化物以及他们的立体异构体在制备治疗和/或预防由CDK激酶介导的癌症相关疾病的药物中的应用。